تداخل‌های دارویی
Amivantamab + Lazertinib
شدت: متوسط
Amivantamab and Lazertinib: moderate interaction.
آخرین به‌روزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
معنای این تداخل به زبان ساده
Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Amivantamab belongs to Oncology; Lazertinib belongs to Oncology.
چرا رخ می‌دهد
The combination increases thromboembolic risk by an incompletely established mechanism.
اقدام لازم
Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
از داروساز چه بپرسید
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Amivantamab و Lazertinib، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
پرسش‌های متداول
Can I take Amivantamab with Lazertinib?
MediHelp rates the interaction as moderate. Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
How serious is the interaction between Amivantamab and Lazertinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
